ROCHESTER — Cytotheryx, an emerging biotechnology company focused on developing treatments for liver disease, has recently completed the acquisition of the two Rochester facilities it currently occupies for a total of $7.6 million.
The firm employs genetically engineered pigs, referred to as ‘proprietary bio-incubators’, to produce human liver cells, which are critical for various medical applications.